Seth Lederman Buys 15,000 Shares of Tonix Pharmaceuticals (NASDAQ:TNXP) Stock

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Seth Lederman bought 15,000 shares of the company’s stock in a transaction on Wednesday, March 18th. The stock was purchased at an average cost of $14.89 per share, with a total value of $223,350.00. Following the completion of the transaction, the chief executive officer owned 15,001 shares in the company, valued at $223,364.89. This represents a 1,500,000.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Tonix Pharmaceuticals Price Performance

Shares of NASDAQ:TNXP opened at $15.77 on Friday. The firm has a market capitalization of $211.40 million, a PE ratio of -1.11 and a beta of 1.88. Tonix Pharmaceuticals Holding Corp. has a 1 year low of $13.07 and a 1 year high of $69.97. The firm’s 50-day moving average is $15.59 and its two-hundred day moving average is $18.55.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($3.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.16) by ($0.82). Tonix Pharmaceuticals had a negative net margin of 946.22% and a negative return on equity of 60.15%. The business had revenue of $5.39 million during the quarter, compared to analyst estimates of $2.97 million. Analysts expect that Tonix Pharmaceuticals Holding Corp. will post -1762.5 EPS for the current fiscal year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in TNXP. Man Group plc acquired a new position in Tonix Pharmaceuticals in the fourth quarter valued at approximately $288,000. Engineers Gate Manager LP raised its holdings in Tonix Pharmaceuticals by 63.7% during the fourth quarter. Engineers Gate Manager LP now owns 14,263 shares of the company’s stock worth $223,000 after purchasing an additional 5,550 shares in the last quarter. Balyasny Asset Management L.P. purchased a new stake in shares of Tonix Pharmaceuticals during the 4th quarter worth approximately $2,895,000. AQR Capital Management LLC purchased a new stake in shares of Tonix Pharmaceuticals during the 4th quarter worth approximately $313,000. Finally, Price T Rowe Associates Inc. MD acquired a new position in shares of Tonix Pharmaceuticals in the 4th quarter valued at $171,000. Hedge funds and other institutional investors own 82.26% of the company’s stock.

Key Headlines Impacting Tonix Pharmaceuticals

Here are the key news stories impacting Tonix Pharmaceuticals this week:

• Positive Sentiment: CEO Seth Lederman bought 15,000 shares at roughly $14.89, a meaningful insider purchase that signals management confidence and often supports investor sentiment. Read More.
• Positive Sentiment: Tonix will present at BIO‑Europe Spring (Mar 24), giving management exposure to potential partners and investors; such conference presentations can boost business‑development visibility and near‑term interest. Read More.
• Positive Sentiment: The company also announced AACR 2026 oral/poster presentations on its preclinical immuno‑oncology programs, which could add scientific validation and partnership upside if data are well‑received. Read More.
• Neutral Sentiment: Q4 results were mixed: revenue beat consensus but EPS missed, pointing to early commercial traction for products yet continued margin and profitability pressure — investors will be watching guidance and cash‑runway commentary. Read More.
• Neutral Sentiment: Institutional ownership is high and some large funds have recently added positions, which can amplify moves (both up and down) as block trades and flows occur. Read More.
• Negative Sentiment: Noble Financial revised several FY/Qtr EPS forecasts, increasing the projected full‑year loss and cutting some quarterly estimates — analyst downgrades and wider loss expectations can weigh on sentiment despite positive headlines. Read More.

Analyst Ratings Changes

Several analysts have recently issued reports on TNXP shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research note on Wednesday, January 21st. Wall Street Zen raised Tonix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, January 17th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold”.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.